Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore Richard Law - Goldman Sachs Annabel Samimy - Stifel Mohit Bansal - Wells Fargo Rami Katkhuda - LifeSci Capital Operator Welcome to the Mineralys Therapeutics Second Quarter 2024 Conference C ...

| --- | --- | --- | |------------------------------------------------------------------|-------|-------| | | | | | | | | | Targeting Aldosterone in the Treatment of Cardiorenal Diseases | | | | J une 2024 | | | F o r w a r d-L o o k i n g S t a t e m e n t s a n d M a r k e t D a t a We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.0001 par value per share MLYS The Nasdaq Stock Market LLC Large accelerated filer o Accelerated filer o Non-accelerated filer x Smaller reporting company x Emerging growth company x Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ¨ ...

Exhibit 99.1 Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update – Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 – – Enrollment ahead of schedule in Phase 3 pivotal Launch-HTN trial and on track to deliver topline data as anticipated in 2H 2025 – – Ongoing Explore-CKD Phase 2 trial is ramping up enrollment under the amended protocol and is anticipated to deliver topline data in 1H 2025 – – Conference ca ...

"We are delighted to welcome Alex to our Board of Directors as we advance the late-stage clinical development of lorundrostat for the treatment of hypertension and related cardiorenal metabolic disorders," stated Jon Congleton, Chief Executive Officer of Mineralys. "As a cardiologist and accomplished biopharmaceutical clinical development executive, Alex brings tremendous experience driving value for biopharmaceutical companies. We believe Alex's track record of successful pipeline development, regulatory a ...

"I am honored to join the Mineralys Board of Directors," stated Dr. Gold. "I look forward to working with the Company's executive team and fellow Board members to advance the treatment of cardiorenal metabolic disorders. There is significant potential with lorundrostat in offering a targeted treatment approach for hypertension and other diseases driven by dysregulated aldosterone." "The Board and I would like to express our collective gratitude to Olivier for his contributions and dedication to the Board. W ...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Garth Russell – LifeSci Advisors Jon Congleton – Chief Executive Officer Adam Levy – Chief Financial Officer David Rodman – Chief Medical Officer Conference Call Participants Jack Padovano – Stifel Seamus Fernandez – Guggenheim Securities Michael DiFiore – Evercore Rami Katkhuda – LifeSci Capital Rich Law – Goldman Sachs Mohit Bansal – Wells Fargo Operator Good morning, ladies and gentleme ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-41614 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-1966887 (Sta ...

Exhibit 99.1 Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update – Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in Q4 2024 – – Ongoing Phase 3 pivotal Launch-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in 2H 2025 – – Ongoing Explore-CKD Phase 2 trial is anticipated to deliver topline data in Q4 2024 to Q1 2025 – – Conference call today at 8:30 a.m ...

Minji Kim, PhD. Chief Business Officer 20+ years of experience: Affamed, Jounce, Curis, Hoffman-LaRoche, Genentech Cindy Berejikian Balance sheet supports activities to execute on upcoming milestones | --- | --- | --- | |------------------------------------------------------------------|-------|-------| | | | | | | | | | Targeting Aldosterone in the Treatment of Cardiorenal Diseases | | | | Mar ch 2024 | | | We caution you that this presentation contains forward-looking statements. All statements other than ...